Lemborexant

Insomnia market report forecasts growth from 2020 to 2034, driven by increasing prevalence, awareness, and emerging therapies like Seltorexant and TS-142. Challenges include high treatment costs and patient non-compliance, with unmet needs for long-term solutions with minimal side effects.

Eisai reports 3% Q2 FY2024 revenue growth to JPY 385 billion, driven by a 5% increase in the pharmaceutical segment, led by Lenvima, Dayvigo, and LEQEMBI. Despite a decline in operating profit due to increased SG&A expenses, the company maintains its full-year forecast and announces an interim dividend of JPY 80 per share. LEQEMBI's U.S. launch contributes JPY 16.3 billion in H1 sales, with 10,000 patients ready for treatment, though 6,000 face infusion delays. Eisai focuses on expanding infusion capacity and improving amyloid beta testing efficiency to enhance patient access and future profitability.

Eisai reports 3% Q2 FY2024 revenue growth to JPY 385 billion, driven by a 5% increase in its pharmaceutical segment. Despite a slight dip in operating profit to JPY 27.8 billion, flagship products like LEQEMBI show promising growth. LEQEMBI sales reach JPY 16.3 billion globally in H1 FY2024, with significant growth in the U.S. and China. The company maintains full-year revenue and profit forecasts and announces an interim dividend of JPY 80 per share. Eisai focuses on cost control and key product growth, with optimism for future market expansion despite infusion capacity constraints delaying treatment for 6,000 patients.